Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (517)	3/29/2001 3:40:49 PM
From: tuck	Respond to of 1784

PB, Many thanks for that most timely pointer. I would guess these systems aren't going to sell like hot cakes until the bugs mentioned are worked out. As such, Trickle will instead take a wait and see approach with CALP, since this is their main product. I am always interested in hearing about actual experiences with Trickle, and I wish folks like niptuck, you, TD, and other lab workers (you know who you are) would post more stuff like that here. Unfortunately I can't offer more incentive than praise and a beer should you come to San Diego, but hopefully that will be enough for some of you. Cheers, Tuck

To: Pseudo Biologist who wrote (517)	4/3/2001 12:30:00 AM
From: tuck	Read Replies (1) \| Respond to of 1784

PB, What do you make of this? Anybody know this private oufit here in S.D.? >>TOOLS AND TECHNOLOGY Don't Clone Those Genes! TAP Express enables speedy, "cloning-free" gene expression By Deborah Fitzgerald If the expression products of a large number of different genes need to be rapidly analyzed, for instance during functional genomic research, consider the Transcriptionally Active PCR (TAP) Express™ Rapid Gene Expression kit from Gene Therapy Systems (GTS) Inc. of San Diego. TAP Express is the first commercially available system for the construction of transcriptionally active PCR fragments that can be expressed in mammalian cells.<< The rest at: the-scientist.com The relevant abstract was published in Nature Biotechnology, and they wanted seven bucks for it. Is this something you would use? Cheers, Tuck

To: Pseudo Biologist who wrote (517)	4/23/2001 12:45:00 PM
From: tuck	Read Replies (1) \| Respond to of 1784

PB, Or anyone who thinks they're qualified. What do you make of this product? >>Harvard Bioscience, Inc. Launches New ADMET Product HOLLISTON, Mass., Feb 27, 2001 /PRNewswire via COMTEX/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO chart, msgs) today announced the introduction of ScanTox(TM), a drug safety evaluation tool that provides a more sensitive means of lead optimization than currently available, as well as an in vitro alternative to the much criticized Draize irritancy test using live animals. newscom.com ScanTox(TM) is designed to reduce the number of drug candidate "false positives" inexpensively before reaching high-cost pre-clinical and clinical trials (Phase II/III). ScanTox(TM) is a laser-based instrument that quantifies the relative cytotoxicity of a substance within a living and functional cultured bovine lens. With high repeatability ScanTox(TM) measures organ functionality of this system, and in turn can be used to measure recovery from toxic agents even at parts per million concentrations. "We believe ScanTox(TM) is a breakthrough product. It perfectly fits our strategy of providing higher relevance and speed at lower cost," said David Green, President of Harvard Bioscience. " For anyone interested as well in accuracy and reproducibility, or concerned with reducing the use of live animals in research and industry, this product is a significant innovation. Like many of our products, ScanTox(TM) can substantially reduce product time to market. During March 26 through 28 we will be demonstrating ScanTox(TM) at the Society of Toxicology trade show in San Francisco and in June we will be at the Congress on In Vitro Biology meeting in St Louis."<< snip HBIO reports Wednesday. Trickle is scared, because HBIO will be entering the lock-up expiration zone soon, but increasingly curious, because . . . You all are aware of my position on laboratory animals. Hence the line about this ADMET product being an alternative to Draize testing caught my eye. HBIO is down hard as I write, and Trickle is tempted to nibble a few shares just in case earnings are good. I think the general market downdraft will continue tomorrow, so I'll try it then. Anybody know how they'd go about culturing a bovine lens? That is, are they getting material from slaughtered cattle, or what? Related, XGEN, which specializes in getting data out of live critters, finally withdrew its IPO prospectus. Appears to be rare good timing on CALP and DPII trades. Trickle gives himself a small pat on the back. Cheers, Tuck